---
title: 'Life Sciences Daily Summary: What Happened on November 13, 2026'
headline: Windward raises $225 million in IPO and Sanofi investment
description: Neurosterix secured $105 million, a melanoma vaccine cut recurrence risk
  in Phase 3, and Lilly broke ground on a Pennsylvania plant.
url: https://thebench.bio/news/summaries/2026-11-13
topic: all
date: '2026-11-13'
covers:
- '2026-11-13'
date_published: '2026-11-13T12:04:27Z'
date_modified: '2026-11-14T00:05:21Z'
tags:
- Industry
- Funding
- Manufacturing
- Clinical
- Regulatory
sources: 12
publisher: TheBench.Bio
---

# Life Sciences Daily Summary: What Happened on November 13, 2026

**Windward raises $225 million in IPO and Sanofi investment**

Neurosterix secured $105 million, a melanoma vaccine cut recurrence risk in Phase 3, and Lilly broke ground on a Pennsylvania plant.

## Today in brief

Windward Bio raised $175 million in its Nasdaq IPO and arranged a separate $50 million investment from Sanofi. [1] [2] Its lead antibody, WIN378, is in Phase 3 testing for severe asthma, with further results expected in 2027 and 2029. [1] [2]

Merck and Moderna’s personalized melanoma vaccine lowered recurrence or death risk by 42% when added to pembrolizumab. Pelacarsen missed its primary endpoint in a separate Phase 3 trial. [3] [4] Neurosterix raised $105 million to advance NTX-253 and other neuropsychiatric drug candidates. [5] [6]

## Windward raises $225 million to fund respiratory drugs

Windward Bio priced its Nasdaq IPO at $17 a share, raising $175 million. A private placement with Sanofi will bring in another $50 million. [1] [2] The combined $225 million will support two programs in respiratory disease and immunology, including WIN378 for asthma and chronic obstructive pulmonary disease (COPD). [1] [2]

WIN378 targets thymic stromal lymphopoietin, or TSLP, the same pathway targeted by Tezspire, an asthma drug from Amgen and AstraZeneca. [2] Windward is testing WIN378 in the Phase 3 portion of a Phase 2/3 study for severe asthma and says the antibody is designed for dosing every six months. [2] The company expects preliminary results from its pivotal asthma studies in the first half of 2029 and estimates the new funds will cover operations through then. [1] [2]

Windward’s other clinical candidate, WIN027, targets both TSLP and interleukin-13 and is in Phase 1 testing. [2] The company expects Phase 2 asthma and COPD data for WIN378 and Phase 1 results for WIN027 in 2027. [1]

## Neurosterix raises $105 million for neuropsychiatric pipeline

Neurosterix raised $105 million in a Series B led by RTW Investments to advance drug candidates for schizophrenia, mood disorders and other psychiatric conditions. [5] [6] Its lead candidate, NTX-253, is an oral muscarinic M4 positive allosteric modulator. It is designed to amplify the receptor’s response to acetylcholine rather than directly activate or block it. [5] [6]

Neurosterix completed Phase 1 studies in healthy volunteers and people with stable schizophrenia. The company says the results support once-daily dosing. [6] It plans to move NTX-253 into Phase 2, but clinical efficacy has not been demonstrated. [5] [6] The company is also developing NTX-819 for mood and anxiety disorders and NTX-529 for psychosis and mood-related conditions. [5] [6]

## Melanoma vaccine reduces recurrence risk in Phase 3 trial

After surgery for melanoma, intismeran autogene plus pembrolizumab reduced recurrence or death risk by 42% compared with pembrolizumab alone. [3] [7] The trial enrolled nearly 1,140 patients. Two-year recurrence-free survival was 82% with the combination and 70% with pembrolizumab alone. [3]

More patients stopped treatment in the vaccine-combination group, 16.6% versus 9.5% in the control group. [3] Researchers said longer survival follow-up and more data on immune mechanisms are needed to guide treatment decisions. [3] Merck and Moderna are preparing an FDA filing and anticipate a possible approval in 2027. [3]

## Pelacarsen misses HORIZON trial’s primary endpoint

Pelacarsen failed to meet the primary endpoint in the Phase 3 HORIZON trial, which evaluated the drug as a treatment targeting lipoprotein(a), or Lp(a). [4]

The result does not establish whether other Lp(a)-lowering programs will succeed. [4]

## EMA committee recommends seven medicines and wider uses

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended marketing authorization for seven medicines at its November meeting. [8] The recommendations include Aumseqa for non-small cell lung cancer, Baxfendy for inadequately controlled hypertension and two insulin-aspart biosimilars for diabetes. [8]

The committee backed wider use of Gazyvaro for some adults with systemic lupus erythematosus and Isturisa for children and adolescents aged six and older with Cushing’s syndrome. [8] It recommended indication extensions for nine other medicines already authorized in the European Union, including a dapivirine vaginal ring designed for replacement every three months instead of monthly. [8]

The committee maintained its negative recommendations for two medicines after reconsidering its initial opinions. [8] It also advised women who could become pregnant and use Mounjaro to use contraception. The communication noted limited evidence on tirzepatide’s effects on oral contraceptives in women with obesity, overweight or type 2 diabetes. [8]

## Lilly begins construction on $3.5 billion Pennsylvania plant

Eli Lilly broke ground on a $3.5 billion manufacturing facility in Pennsylvania’s Lehigh Valley. Operations are expected to begin in 2031. [9] [10] Lilly plans to make GLP-1 medicines there, including investigational retatrutide, which is in Phase 3 trials for obesity and other conditions. [9] [10]

Lilly expects the site to employ about 850 people and support roughly 2,000 construction workers. [9] [10] The facility is part of Lilly’s broader $50 billion US manufacturing investment announced since 2020. [9] [10]

## Cellectis plans workforce cuts of up to 70% in strategic shift

Cellectis said its shift to in vivo gene-editing treatments could cut up to 70% of its global workforce. Changes are expected through 2026 and into 2027. [11] The company had 229 full-time employees at the end of 2025, putting the maximum potential reduction at about 160 people. [11]

Cellectis has halted enrollment in its lasme-cel and eti-cel programs and is continuing required follow-up for treated patients. [11] The company plans to test HEAL-101 in China, with initial data expected in the second half of 2027, and begin a Phase 1 study of HEAL-201 there, with preliminary data expected in the first half of 2028. [11]

The proposed restructuring is subject to consultation with the French works council and labor-law requirements in France and the United States. [11] Cellectis reported $149 million in cash and specified financial assets at September 30. It expects that funding to support operations into the second half of 2028. [11]

## Also worth knowing

- The FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor. [12]

## The day in numbers

- **$225 million**: Windward Bio’s combined IPO proceeds and Sanofi private placement. [1] [2]
- **42%**: Lower recurrence or death risk with Merck and Moderna’s melanoma vaccine plus pembrolizumab than with pembrolizumab alone. [3] [7]
- **$105 million**: Neurosterix’s Series B financing. [5] [6]
- **Up to 70%**: Cellectis’s potential workforce reduction as it shifts toward in vivo therapies. [11]
- **$3.5 billion**: Eli Lilly’s investment in its planned Pennsylvania manufacturing facility. [9] [10]

## Sources

1. [Windward raises $175M in IPO, adds $50M from Sanofi](<https://european-biotechnology.com/latest-news/windward-raises-175m-in-ipo-adds-50m-from-sanofi/>), European Biotechnology, 2026-11-13
2. [Windward Bio’s Stock Market Debut Reels In $225M for Better Biologic Drugs](<https://medcitynews.com/2026/11/windward-bio-ipo-long-acting-antibody-tslp-asthma-copd-atopic-dermatitis-wwb/>), MedCity News, 2026-11-13
3. [Cancer vaccine development gets complicated](<https://www.nature.com/articles/d41573-026-00181-8>), Nature Reviews Drug Discovery, 2026-11-13
4. [AHA26: Pelacarsen misses primary endpoint in Phase III HORIZON trial](<https://www.clinicaltrialsarena.com/analyst-comment/aha26-pelacarsen-misses-primary-endpoint-in-phase-iii-horizon-trial/>), Clinical Trials Arena, 2026-11-13
5. [Neurosterix pockets $105m to advance neuropsychiatry pipeline ](<https://www.pharmaceutical-technology.com/news/neurosterix-150m-series-b-to-advance-neuropsychiatry-pipeline-schizophrenia/>), Pharmaceutical Technology, 2026-11-13
6. [Addex spinout Neurosterix raises $105M to advance schizophrenia drug into Phase 2](<https://european-biotechnology.com/latest-news/addex-spinout-neurosterix-raises-105m-to-advance-schizophrenia-drug-into-phase-2/>), European Biotechnology, 2026-11-12
7. [Moderna Lays Out Oncology-Driven Growth Plan at 2026 Analyst Day](<https://www.pharmexec.com/view/moderna-oncology-driven-growth-plan-2026-analyst-day>), Pharmaceutical Executive, 2026-11-12
8. [Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026](<https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2026>), EMA Press, 2026-11-13
9. [Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site](<https://www.pharmexec.com/view/eli-lilly-breaks-ground-3-billion-pennsylvania-manufacturing-site>), Pharmaceutical Executive, 2026-11-13
10. [Lilly breaks ground on $3.5bn manufacturing site in Pennsylvania](<https://www.bioprocessintl.com/facilities-capacity/lilly-breaks-ground-on-3-5bn-manufacturing-site-in-pennsylvania>), BioProcess International, 2026-11-13
11. [Cellectis could cut 70% of workforce in shift to in vivo therapies](<https://www.biospace.com/job-trends/cellectis-could-cut-70-of-workforce-in-shift-to-in-vivo-therapies>), BioSpace, 2026-11-13
12. [ACT Brief: Zip Code Trial Access, Smaller Biotech APAC Perceptions, and Pimjetmi Tumor Approval](<https://www.appliedclinicaltrialsonline.com/view/ip-code-trial-access-smaller-biotech-apac-perceptions-pimjetmi-tumor-approval>), Applied Clinical Trials, 2026-11-13

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://european-biotechnology.com/latest-news/windward-raises-175m-in-ipo-adds-50m-from-sanofi/>
[2]: <https://medcitynews.com/2026/11/windward-bio-ipo-long-acting-antibody-tslp-asthma-copd-atopic-dermatitis-wwb/>
[3]: <https://www.nature.com/articles/d41573-026-00181-8>
[4]: <https://www.clinicaltrialsarena.com/analyst-comment/aha26-pelacarsen-misses-primary-endpoint-in-phase-iii-horizon-trial/>
[5]: <https://www.pharmaceutical-technology.com/news/neurosterix-150m-series-b-to-advance-neuropsychiatry-pipeline-schizophrenia/>
[6]: <https://european-biotechnology.com/latest-news/addex-spinout-neurosterix-raises-105m-to-advance-schizophrenia-drug-into-phase-2/>
[7]: <https://www.pharmexec.com/view/moderna-oncology-driven-growth-plan-2026-analyst-day>
[8]: <https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2026>
[9]: <https://www.pharmexec.com/view/eli-lilly-breaks-ground-3-billion-pennsylvania-manufacturing-site>
[10]: <https://www.bioprocessintl.com/facilities-capacity/lilly-breaks-ground-on-3-5bn-manufacturing-site-in-pennsylvania>
[11]: <https://www.biospace.com/job-trends/cellectis-could-cut-70-of-workforce-in-shift-to-in-vivo-therapies>
[12]: <https://www.appliedclinicaltrialsonline.com/view/ip-code-trial-access-smaller-biotech-apac-perceptions-pimjetmi-tumor-approval>
